[go: up one dir, main page]

AR042668A1 - Derivados de fosfonoxi quinazolinas y su uso farmaceutico - Google Patents

Derivados de fosfonoxi quinazolinas y su uso farmaceutico

Info

Publication number
AR042668A1
AR042668A1 ARP030104824A ARP030104824A AR042668A1 AR 042668 A1 AR042668 A1 AR 042668A1 AR P030104824 A ARP030104824 A AR P030104824A AR P030104824 A ARP030104824 A AR P030104824A AR 042668 A1 AR042668 A1 AR 042668A1
Authority
AR
Argentina
Prior art keywords
alkyl
phosphonooxy
substituted
halo
hydrogen
Prior art date
Application number
ARP030104824A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR042668A1 publication Critical patent/AR042668A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de quinazolina, según composiciones que los contienen, procesos para su preparación, y su uso en terapia como antiproliferativo celular. Reivindicación 1: Un compuesto de fórmula (1), en la cual A es heteroarilo de 5 miembros que contiene un átomo de nitrógeno y opcionalmente contiene uno o dos átomos más de nitrógeno; X es O, S, S(O), S(O)2 o NR14; m es 0,1, 2 ó 3; Z es un grupo seleccionado de -NR1R2, fosfonooxi, cicloalquilo C3-6 (sustituido con fosfonooxi o alquilo C1-4 (sustituido con fosfonooxi)) y un anillo de 4 a 7 miembros unido por un átomo de carbono que contiene un átomo de nitrógeno y que opcionalmente contiene otro átomo de nitrógeno, anillo que puede ser saturado, parcialmente saturado o no saturado, en el cual el anillo está sustituido en carbono o nitrógeno con fosfonooxi o alquilo C1-4 (sustituido con fosfonooxi) y en el cual el anillo se sustituye además, de manera opcional, en el carbono o nitrógeno, con 1, 2 ó 3 grupos halo o alquilo C1-4; R1 es -COR8, -CONR8R9 o alquilo C1-6 (sustituido con fosfonooxi y además de manera opcional sustituido con 1 ó 2 grupos halo o metoxi); R2 es hidrógeno, -COR10, -CONR10R11, alquilo C1-6 (sustituido opcionalmente con 1, 2 ó 3 grupos halo o alcoxi C1-4 o -S(O)pR11 (donde p es 0, 1 ó 2) o fosfonooxi), alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 y cicloalquil(C3-6)-alquilo(C1-4); o R1 y R2 junto con el nitrógeno al cual se encuentran unidos forman un anillo de 4 a 7 miembros que contiene opcionalmente otro átomo de nitrógeno, que puede ser saturado, parcialmente saturado o no saturado, en el cual el anillo está sustituido en carbono o nitrógeno con un grupo seleccionado de fosfonooxi y alquilo C1-4 (sustituido con fosfonooxi o -NR8R9) y donde el anillo está sustituido además de manera opcional en el carbono o nitrógeno con 1, 1 ó 3 grupos halo o alquilo C1-4; R3 es hidrógeno, halo, ciano, nitro, alcoxi C1-6, alquilo C1-6, -OR12, -CHR12R13, -OC(O)R12, -C(O)R12, -NR12C(O)R13, -C(O)NR12R13, -NR12SO2R13 o -NR12R13; R4 es hidrógeno o un grupo seleccionado de alquilo C1-4, heteroarilo, heteroarilalquilo C1-4, arilo y arilalquilo C1-4, grupo que está sustituido de manera opcional con 1, 2 ó 3 sustituyentes seleccionados de halo, metilo, etilo, ciclopropilo y etinilo; R5 se selecciona de hidrógeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6 y cicloalquil C1-4; R6 y R7 son independientemente hidrógeno, halo, alquilo C1-4, cicloalquilo C3-6, hidroxi y alcoxi C1-4; R8 es alquilo C1-4 sustituido con fosfonooxi y además está sustituido opcionalmente con 1 ó 2 grupos halo o metoxi; R9 es hidrógeno o alquilo C1-4; R10 es hidrógeno o alquilo C1-4 (sustituido de manera opcional con halo, alcoxi C1-4, S(O)q (donde q es 0, 1 ó 2) o fosfonooxi); R11, R12, R13 y R14 son independientemente hidrógeno, alquilo C1-4 o heterociclilo; o una sal aceptable para uso farmacéutico del mismo.
ARP030104824A 2002-12-24 2003-12-23 Derivados de fosfonoxi quinazolinas y su uso farmaceutico AR042668A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
AR042668A1 true AR042668A1 (es) 2005-06-29

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030104824A AR042668A1 (es) 2002-12-24 2003-12-23 Derivados de fosfonoxi quinazolinas y su uso farmaceutico
ARP070102117A AR057753A2 (es) 2002-12-24 2007-05-16 Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070102117A AR057753A2 (es) 2002-12-24 2007-05-16 Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen

Country Status (30)

Country Link
US (4) US7528121B2 (es)
EP (2) EP1847539B1 (es)
JP (3) JP4422102B2 (es)
KR (1) KR101010299B1 (es)
AR (2) AR042668A1 (es)
AT (2) ATE438644T1 (es)
AU (1) AU2003290313B2 (es)
BR (1) BRPI0317717B8 (es)
CA (1) CA2511613C (es)
CL (1) CL2003002731A1 (es)
CY (2) CY1107775T1 (es)
DE (2) DE60315892T2 (es)
DK (2) DK1847539T3 (es)
ES (2) ES2290529T3 (es)
HK (2) HK1080481A1 (es)
IL (2) IL169112A (es)
IS (2) IS2504B (es)
MX (1) MXPA05006918A (es)
MY (2) MY136174A (es)
NO (2) NO335193B1 (es)
NZ (1) NZ540698A (es)
PL (2) PL223998B1 (es)
PT (2) PT1847539E (es)
RU (3) RU2350611C1 (es)
SA (1) SA04240504B1 (es)
SI (2) SI1847539T1 (es)
TW (2) TWI336327B (es)
UA (1) UA83814C2 (es)
UY (1) UY28149A1 (es)
WO (1) WO2004058781A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4498741B2 (ja) * 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
CA2511613C (en) 2002-12-24 2012-10-02 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ATE534649T1 (de) * 2003-05-15 2011-12-15 Arqule Inc Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2006040520A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US8138194B2 (en) 2008-04-30 2012-03-20 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
BRPI0914936A2 (pt) * 2008-07-03 2015-10-20 Merck Patent Gmbh naftiridininonas como inibidores de aurora quinase
BRPI0921862A2 (pt) * 2008-12-05 2015-12-29 Arqule Inc inibidores de raf e seus usos
WO2010068861A1 (en) 2008-12-11 2010-06-17 Axcentua Pharmaceutucals Ab Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6301374B2 (ja) * 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
DK3311845T3 (da) 2013-09-16 2020-04-06 Astrazeneca Ab Terapeutiske polymernanopartikler og fremgangsmåder til fremstilling og anvendelse heraf
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
EP4327882A3 (en) 2017-09-08 2024-05-15 The Board of Trustees of the Leland Stanford Junior University Enpp1 inhibitors and their use for the treatment of cancer
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ATE315654T1 (de) 1995-12-18 2006-02-15 Sugen Inc Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HUP0300059A3 (en) 1999-09-21 2003-08-28 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
EP1299381B1 (en) * 2000-06-28 2008-05-07 AstraZeneca AB Substituted quinazoline derivatives and their use as inhibitors
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
JP4498741B2 (ja) * 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
CA2511613C (en) * 2002-12-24 2012-10-02 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo

Also Published As

Publication number Publication date
KR101010299B1 (ko) 2011-01-25
NO20052855D0 (no) 2005-06-13
DE60315892T2 (de) 2008-08-14
RU2007121850A (ru) 2008-12-20
KR20050088333A (ko) 2005-09-05
IL169112A0 (en) 2009-02-11
EP1847539A1 (en) 2007-10-24
DK1847539T3 (da) 2009-11-09
RU2357971C2 (ru) 2009-06-10
EP1578755B1 (en) 2007-08-22
TWI336327B (en) 2011-01-21
PT1578755E (pt) 2007-10-19
WO2004058781A1 (en) 2004-07-15
AR057753A2 (es) 2007-12-19
HK1080481A1 (en) 2006-04-28
BR0317717A (pt) 2005-11-22
NO20052855L (no) 2005-08-03
US9018191B2 (en) 2015-04-28
AU2003290313A1 (en) 2004-07-22
IS7948A (is) 2005-07-20
DE60328735D1 (de) 2009-09-17
SA04240504B1 (ar) 2008-04-01
ATE370958T1 (de) 2007-09-15
RU2350611C1 (ru) 2009-03-27
MY147761A (en) 2013-01-31
TWI393710B (zh) 2013-04-21
US20150307534A1 (en) 2015-10-29
PL223998B1 (pl) 2016-11-30
IL169112A (en) 2010-12-30
TW201102369A (en) 2011-01-16
JP4906608B2 (ja) 2012-03-28
UY28149A1 (es) 2004-07-30
JP4422102B2 (ja) 2010-02-24
DE60315892D1 (de) 2007-10-04
US8268841B2 (en) 2012-09-18
US9567358B2 (en) 2017-02-14
NO335446B1 (no) 2014-12-15
IS2504B (is) 2009-04-15
JP2006512418A (ja) 2006-04-13
DK1578755T3 (da) 2007-11-12
ES2329623T3 (es) 2009-11-27
US20060116357A1 (en) 2006-06-01
IS2884B (is) 2014-06-15
PL377680A1 (pl) 2006-02-06
BRPI0317717B1 (pt) 2017-12-19
PL412704A1 (pl) 2015-10-12
CY1109479T1 (el) 2014-08-13
IL185176A0 (en) 2007-12-03
CY1107775T1 (el) 2013-06-19
MXPA05006918A (es) 2005-08-18
IL185176A (en) 2011-10-31
SA04240504A (ar) 2005-12-03
AU2003290313B2 (en) 2007-05-10
JP4503090B2 (ja) 2010-07-14
EP1847539B1 (en) 2009-08-05
UA83814C2 (ru) 2008-08-26
ATE438644T1 (de) 2009-08-15
HK1111417A1 (en) 2008-08-08
PL221490B1 (pl) 2016-04-29
US20100069412A1 (en) 2010-03-18
US7528121B2 (en) 2009-05-05
PT1847539E (pt) 2009-10-06
SI1578755T1 (sl) 2007-12-31
JP2009046514A (ja) 2009-03-05
CA2511613C (en) 2012-10-02
BRPI0317717B8 (pt) 2021-05-25
NO335193B1 (no) 2014-10-20
RU2005123485A (ru) 2006-03-10
SI1847539T1 (sl) 2010-01-29
NZ540698A (en) 2008-05-30
CL2003002731A1 (es) 2005-01-07
MY136174A (en) 2008-08-29
CA2511613A1 (en) 2004-07-15
NO20131444L (no) 2005-08-03
US20140162984A1 (en) 2014-06-12
EP1578755A1 (en) 2005-09-28
IS8714A (is) 2008-02-13
JP2007326862A (ja) 2007-12-20
ES2290529T3 (es) 2008-02-16
TW200510342A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR088449A1 (es) Benzilindazoles sustituidos
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20060238A1 (es) Inhibidores de integrasa del virus de inmunodeficiencia humana: compuestos de pirimidinona ciclica
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR049263A1 (es) Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
CO5700768A2 (es) Derivados de benzoxazina y sus usos
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ECSP045073A (es) Nuevos derivados de piperazina
RU2011116160A (ru) Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.
PH12017501655B1 (en) Morphinan derivative
PE20212327A1 (es) Ciertos compuestos de pladienolida y metodos de uso

Legal Events

Date Code Title Description
FG Grant, registration